Asia Pacific Rare Neurological Disease Treatment Market Forecast to 2027 - Covid-19 Impact and Regional Analysis by Indication (Narcolepsy, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Multiple Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Other Indication); Drug Type (Organic Compounds, Biologics); Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies); Mode of Administration (Oral, Injectables) and Country
The Asia Pacific rare neurological disease treatment market is expected to reach US$ 2,437.02 Mn in 2027 from US$ 1,225.38 Mn in 2019. The market is estimated to grow with a CAGR of 9.2% from 2019-2027.
The growth of the market is driven by factors such as the rising prevalence of rare neurological diseases, increasing awareness about rare diseases, and robust pipeline drugs in the Asia Pacific region. However, higher cost of rare neurological disease treatments is likely to restrain the market growth to a certain extent.
A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease. These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body. There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people.
Rapid developments in healthcare and drug discovery are leading to the introduction of new therapeutic solutions for the treatment of rare neurological diseases. Authorities such as World Health Organization are taking constructive steps to encourage the research activities to find a remedy for rare neurological disease treatment. For instance, in recent decades, considerable attention has been paid worldwide to stimulate the research, development and marketing of medicinal products for rare diseases. In Singapore, Axsome Therapeutics, Inc. is developing revolutionary therapies for central nervous system disorders (CNS), namely AXS-12 for narcolepsy treatment. Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period.
The frequency of neurological disorders has increased significantly across Asia Pacific. These disorders are estimated to affect over a billion population, according to the World Health Organization in 2016. Neurological disorders are commonly found among population, irrespective of the age groups, and geographic region. In the recent years, various measures have been implemented to generate awareness and educate the population regarding rare neurological diseases, which is facilitating patients to access the suitable medications and treatments for these conditions. Factors such as rising incidences of chronic illnesses, an increase in the aging population, and pediatric care, are boosting the growth of the healthcare industry. The increasing awareness among patients and developing healthcare infrastructure are likely to offer significant opportunity for the growth of the market.
The increasing use of rare neurological disease treatment in medical treatment cases in Asia Pacific is expected to drive rare neurological disease treatment market the growing pharmaceuticals industry in the country create a lucrative opportunity and the presence of an established market for rare neurological disease treatment.
Rest of Asia Pacific Rare neurological disease treatment Market Revenue and Forecasts to 2027 (US$ Bn)
Get more information on this report :
ASIA PACIFIC RARE NEUROLOGICAL DISEASE TREATMENT – MARKET SEGMENTATION
Asia Pacific Rare Neurological Disease Treatment Market - By Indication
- Narcolepsy
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Multiple Sclerosis
- Spinal Muscular Atrophy (SMA)
- Duchenne Muscular Dystrophy
- Other Indications
Asia Pacific Rare Neurological Disease Treatment Market - By Drug Type
- Organic Compounds
- Biologics
Asia Pacific Rare Neurological Disease Treatment Market - By Distribution Channel
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Asia Pacific Rare Neurological Disease Treatment Market - By Mode of Administration
Asia Pacific Rare Neurological Disease Treatment Market - By Country
- Japan
- China
- India
- Australia
- South Korea
Companies Mentioned
- Allergan plc.
- Bayer AG
- GlaxoSmithKline plc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Limited
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Rare Neurological Disease Treatment Market – By Indication
1.3.2 Asia Pacific Rare Neurological Disease Treatment Market – By Drug Type
1.3.3 Asia Pacific Rare Neurological Disease Treatment Market – By Distribution Channel
1.3.4 Asia Pacific Rare Neurological Disease Treatment Market – By Mode of Administration
1.3.5 Asia Pacific Rare Neurological Disease Treatment Market – By Country
2. Asia Pacific Rare Neurological Disease Treatment Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Rare Neurological Disease Treatment Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Rare Neurological Disease Treatment Market - Asia Pacific PEST Analysis
4.3 Expert Opinion
5. Asia Pacific Rare Neurological Disease Treatment Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Rare Neurological Diseases
5.1.2 Favourable Pipeline Drugs and Robust Research Activities for the Treatment of Rare Neurological Diseases
5.2 Key Restraints
5.2.1 High Treatment Cost for Rare Neurological Diseases
5.3 Key Market Opportunities
5.3.1 Increasing Awareness of Rare Neurological Diseases Coupled with Developing Healthcare Infrastructure
5.4 Future Trend
5.4.1 Artificial Intelligence for the Treatment of Rare Neurological Diseases
5.5 Impact Analysis
6. Rare Neurological Disease Treatment Market – Asia Pacific Analysis
6.1 Asia Pacific Rare Neurological Disease Treatment Market Revenue Forecasts and Analysis
7. Asia Pacific Rare Neurological Disease Treatment Market Analysis and Forecasts To 2027 – By Indication
7.1 Overview
7.2 Asia Pacific Rare Neurological Disease Treatment Market, By Indication 2019 & 2027 (%)
7.2.1 Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Indication (US$ Mn)
7.3 Narcolepsy
7.3.1 Overview
7.3.2 Asia Pacific Narcolepsy Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Amyotrophic Lateral Sclerosis
7.4.1 Overview
7.4.2 Asia Pacific Amyotrophic Lateral Sclerosis Market Revenue and Forecast to 2027 (US$ Mn)
7.5 Alzheimer’s Disease
7.5.1 Overview
7.5.2 Asia Pacific Alzheimer’s Disease Market Revenue and Forecast to 2027 (US$ Mn)
7.6 Multiple Sclerosis
7.6.1 Overview
7.6.2 Asia Pacific Multiple Sclerosis Market Revenue and Forecast to 2027 (US$ Mn)
7.7 Spinal Muscular Atrophy (SMA)
7.7.1 Overview
7.7.2 Asia Pacific Spinal Muscular Atrophy Market Revenue and Forecast to 2027 (US$ Mn)
7.8 Duchenne Muscular Dystrophy
7.8.1 Overview
7.8.2 Asia Pacific Duchenne Muscular Dystrophy Market Revenue and Forecast to 2027 (US$ Mn)
7.9 Other Indications
7.9.1 Overview
7.9.2 Asia Pacific Other Indications Market Revenue and Forecast to 2027 (US$ Mn)
8. Asia Pacific Rare Neurological Disease Treatment Market Analysis– By Drug Type
8.1 Overview
8.2 Asia Pacific Rare Neurological Disease Treatment Market, By Drug Type 2019-2027 (%)
8.2.1 Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Drug Type (US$ Mn)
8.3 Organic Compounds
8.3.1 Overview
8.3.2 Asia Pacific Organic Compounds Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Biologics
8.4.1 Overview
8.4.2 Asia Pacific Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
9. Asia Pacific Rare Neurological Disease Treatment Market Analysis– By Distribution Channel
9.1 Overview
9.2 Asia Pacific Rare Neurological Disease Treatment Market, By Distribution Channel 2019 & 2027 (%)
9.2.1 Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
9.3 Online Pharmacies
9.3.1 Overview
9.3.2 Asia Pacific Online Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Asia Pacific Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Retail Pharmacies
9.5.1 Overview
9.5.2 Asia Pacific Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10. Asia Pacific Rare Neurological Disease Treatment Market Analysis– By Mode of Administration
10.1 Overview
10.2 Asia Pacific Rare Neurological Disease Treatment Market, By Mode of Administration 2019 & 2027 (%)
10.2.1 Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts to 2027, By Mode of Administration (US$ Mn)
10.3 Oral
10.3.1 Overview
10.3.2 Asia Pacific Oral Market Revenue and Forecast to 2027 (US$ Mn)
10.4 Injectable
10.4.1 Overview
10.4.2 Asia Pacific Injectable Market Revenue and Forecasts to 2027 (US$ Mn)
11. Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027
11.1.1 Overview
11.1.2 Asia Pacific: Rare Neurological Disease Treatment Market - Revenue and Forecast to 2027 (USD Million)
11.1.3 Asia Pacific: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.4 Asia Pacific: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.5 Asia Pacific: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.6 Asia Pacific: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.7 Asia Pacific: Rare Neurological Disease Treatment Market, by Country, 2019& 2027 (%)
11.1.8 China: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 China: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 China: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.8.3 China: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.8.4 China: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.8.5 China: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.9 Japan: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Japan: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Japan: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.9.3 Japan: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.9.4 Japan: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.9.5 Japan: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.10 India: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 India: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 India: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.10.3 India: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.10.4 India: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.10.5 India: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.11 South Korea: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.1 South Korea: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.2 South Korea: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.11.3 South Korea: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.11.4 South Korea: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.11.5 South Korea: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.12 Australia: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.1 Australia: Rare Neurological Disease Treatment Market, by Indication, 2018–2027 (USD Million)
11.1.12.2 Australia: Rare Neurological Disease Treatment Market, by Drug Type, 2018–2027 (USD Million)
11.1.12.3 Australia: Rare Neurological Disease Treatment Market, by Mode of Administration, 2018–2027 (USD Million)
11.1.12.4 Australia: Rare Neurological Disease Treatment Market, by Distribution Channel, 2018–2027 (USD Million)
12. Impact Of COVID-19 Pandemic On Global Rare Neurological Diseases Treatment Market
12.1 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
13. Asia Pacific Rare Neurological Disease Treatment Market Industry Landscape
13.1 Overview
13.2 Organic Growth Strategies
13.2.1 Overview
14. Company Profiles
14.1 Takeda Pharmaceutical Company Limited
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Bayer AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Johnson & Johnson Services, Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Novartis AG
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Pfizer Inc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Indication (US$ Mn)
Table 2. Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Drug Type (US$ Mn)
Table 3. Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
Table 4. Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecasts To 2027, By Mode of Administration (US$ Mn)
Table 5. Asia Pacific Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 6. Asia Pacific Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 7. Asia Pacific Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 8. Asia Pacific Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 9. China Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 10. China Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 11. China Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 12. China Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Japan Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 14. Japan Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 15. Japan Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 16. Japan Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 17. India Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 18. India Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 19. India Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 20. India Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 21. South Korea Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 22. South Korea Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 23. South Korea Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 24. South Korea Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 25. Australia Rare Neurological Disease Treatment Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 26. Australia Rare Neurological Disease Treatment Market, by Drug Type – Revenue and Forecast to 2027 (USD Million)
Table 27. Australia Rare Neurological Disease Treatment Market, by Mode of Administration – Revenue and Forecast to 2027 (USD Million)
Table 28. Australia Rare Neurological Disease Treatment Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 29. Recent Inorganic Growth Strategies In The Rare Neurological Disease Treatment Market
Table 30. Recent Organic Growth Strategies In The Rare Neurological Disease Treatment Market
Table 31. Glossary of Terms, Rare Neurological Disease Treatment Market
LIST OF FIGURES
Figure 1. Rare Neurological Disease Treatment Market Segmentation
Figure 2. Asia Pacific Rare Neurological Disease Treatment Market Overview
Figure 3. Alzheimer’s Disease Segment Held Largest Share of Indication Segment in Rare Neurological Disease Treatment Market
Figure 4. China Is Expected To Show Remarkable Growth During The Forecast Period
Figure 5. Asia Pacific Rare Neurological Disease Treatment Market- Leading Country Markets (US$ Mn)
Figure 6. Rare Neurological Disease Treatment Market, Industry Landscape
Figure 7. Rare Neurological Disease Treatment Market - Asia Pacific PEST Analysis
Figure 8. Rare Neurological Disease Treatment Market Impact Analysis of Drivers and Restraints
Figure 9. Asia Pacific Rare Neurological Disease Treatment Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 10. Asia Pacific Rare neurological disease treatment Market, By Indication 2019 & 2027 (%)
Figure 11. Asia Pacific Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Asia Pacific Amyotrophic Lateral Sclerosis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Asia Pacific Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Asia Pacific Multiple Sclerosis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Asia Pacific Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Asia Pacific Duchenne Muscular Dystrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Asia Pacific Other Indications Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Asia Pacific Rare Neurological Disease Treatment Market, by Drug Type 2019 & 2027 (%)
Figure 19. Asia Pacific Organic Compounds Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Asia Pacific Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Asia Pacific Rare Neurological Disease Treatment Market, By Distribution Channel 2019 & 2027 (%)
Figure 22. Asia Pacific Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Asia Pacific Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Asia Pacific Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Asia Pacific Rare Neurological Disease Treatment Market, By Mode of Administration 2019 & 2027 (%)
Figure 26. Asia Pacific Oral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. Asia Pacific Injectable Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 28. Asia Pacific: Rare Neurological Disease Treatment Market, by Key Country – Revenue (2019) (USD Million)
Figure 29. Asia Pacific Rare Neurological Disease Treatment Market Revenue and Forecast to 2027 (USD Million)
Figure 30. China: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Japan: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. India: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 33. South Korea: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. Australia: Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (USD Million)
Figure 35. Impact of COVID-19 Pandemic In Asia Pacific Country Markets
The List of Companies - Asia Pacific Rare Neurological Disease Treatment Market
- Allergan plc.
- Bayer AG
- GlaxoSmithKline plc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Limited
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the APAC rare neurological disease treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe rare neurological disease treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.